The Veeva 2020 Study Start-up Pulse Report examines the life sciences industry’s progress toward streamlining study start-up by gathering the experiences and opinions of over 500 clinical operations professionals from around the globe. The goal of the research is to understand the drivers, barriers, and benefits of modernizing clinical systems and processes to accelerate trials and gives an industry-wide view of study start-up technology adoption.
Findings show an urgent need to streamline study start-up processes to increase operational efficiency, quality, and speed in clinical trials.
- All respondents say they need to improve study start-up processes. The top drivers are faster study start-up times (75%) and reduced manual processes (53%).
- Nearly all respondents (98%) report significant challenges with study start-up, likely due to the heavy reliance on manual processes since most (81%) use spreadsheets to manage this area.
- More than one-third say faster collection of site essential documents (44%) and easier collaboration (42%) are critical to improving study start-up.
- Majorities say automating key study start-up processes like contracts and budgets (63%) and site essential document collection (61%) would have a significant, positive impact on trial quality and speed.